ClinicalTrials.gg
RecruitingNCT06624969Updated May 5, 2026

Virtual Reality in Reducing Acute Orthopedic Pain

An interventional study of virtual reality in Fractures, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary aim of this research is to show that a virtual reality (VR) service line is feasible and can sustain itself with the ability to take care of patients. Additionally, the investigators aim to learn about the limitations of a service line and provide a pathway for future improvements in building a VR service line that is optimally aligned with the user's needs. Secondary aims are to evaluate the clinical aspects of the patient's outcomes including length of stay, morphine equivalents in pain medicine required during the hospital stay, and user experiences.

02

Conditions studied

  • Fractures

Browse trials for

Keywords

  • pain control
  • orthopedic
  • fracture
  • hospital
03

In context

Fractures, Bone

723 studies on the registry are indexed under Fractures, Bone; 114 are open to participants now.

This study's planned enrollment of 100 is above the median of 80 across 458 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized with an orthopedic fracture
  2. Able to participate fully in all aspects of the study
  3. Able to understand and sign
  4. Individuals with unaided vision or those who can correct their vision using contact lenses

Exclusion criteria

Exclusion Criteria:

  1. Non-English speaking
  2. Self-reported history of acute and/or chronic severe motion sickness
  3. The presence of a facial/head deformity that will prohibit the wearing of a VR head mounted display.
  4. Legally blind or deaf
  5. Have had a seizure within the past 1 year
  6. Have current (within the past 30 days) acute or chronic progressive or unstable/uncontrolled neurologic disorder
  7. Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Virtual reality

    Intervention with virtual reality

    Other: virtual reality

  • No intervention
    Standard of care

    No virtual reality intervention

Interventions

  • Othervirtual reality

    Virtual reality program to reduce pain in orthopedic fractures

06

What researchers measure

Primary outcomes

  1. opioid use

    Change in opioid equivalents during hospital stay from hospital admission to discharge

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

Secondary outcomes

  1. reduction in anxiolytics

    Change in anxiolytics during the hospital admission from admission to discharge

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

  2. hospital length of stay

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

  3. reduction in sleep aids prescribed

    Change in sleep aids prescribed during the hospital stay from hospital admission to discharge

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

  4. User experiences

    Subjective user experiences with the virtual reality program obtained at hospital discharge using a questionnaire with Likert scale answers showing higher scores to have better experiences with the intervention

    Time frame: obtained once on the day of hospital discharge, up to 5 weeks from study enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Of 148 non-industry interventional studies with no phase under Fractures, Bone, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 57. This study's planned 21 months is below that.

Counting every sponsor, half of 166 studies reached it within 29 months; a quarter within 12 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Oct 3, 2024
StartActual
Apr 23, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Dec 2028
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06624969
Lead sponsor
Mayo Clinic
Responsible party
Scott A. Helgeson (Consultant, Assistant Professor of Medicine, Mayo Clinic) — Principal investigator
First posted
Oct 3, 2024
Start date
Apr 23, 2026
Primary completion
Jan 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 5, 2026

Study contacts

Scott Helgeson, MD
Contact
helgeson.scott@mayo.edu
904-953-2000
Scott Helgeson, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion